1005009-95-9

Basic information

• Product Name: 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• Synonyms: 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS NO: 1005009-95-9
• Molecular Weight: 292.183
• Mol File: 1005009-95-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 382.1±32.0 °C(Predicted)
• Density: 1.03±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1005009-95-9)
• EPA Substance Registry System: 2-(3,4-diethoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(1005009-95-9)

Safety Data

• Hazardous Substances Data: 1005009-95-9(Hazardous Substances Data)

Upstream product

• 17345-77-6 1-bromo-3,4-dihydroxybenzene 
• 53207-08-2 4-bromo-1,2-diethoxybenzene 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 69373-87-1 ethyl 2-(3,4-diethoxyphenyl)acetate 
• 6298-46-0 N-(3,4-diethoxyphenylacetyl)-β-(3,4-diethoxyphenyl)ethylamine 
• 911-60-4 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline hydrochloride 
• 38464-04-9 3,4-diethoxy-phenyl-acetic acid 
• 61381-04-2 2-(3,4-diethoxyphenyl)ethylamine 

Relevant articles and documents

Boron Containing PDE4 Inhibitors

The present invention relates to boron containing compounds of Formula (I) [in-line-formulae]X—Y—Z?? Formula (I)[/in-line-formulae] that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.

1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

The invention relates to the use of 1H-imidazo[4,5-c]quinolinone derivatives and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c] quinolinone derivatives for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H- imidazo[4,5-c] quinofinone derivatives to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c] quinolinone derivative, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H- imidazo[4,5-c] quinolinone derivatives; and a process for the preparation of the novel 1H- imidazo[4,5-c] quinolinone derivatives.